Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen Ophthalmic Solution 0.5 mg/ml in Seasonal Allergic Conjunctivitis
2023-503185-23-00Phase 3Completed
- Sponsor
- Genetic
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketotifen hydrogen fumarate in seasonal allergic conjunctivitis (SAC) (3 arms), sponsored by Genetic. Primary endpoint: Change in ocular itching score from baseline to Day 14. Started May 2023; status: completed.
02
Drugs
ketotifen hydrogen fumarate
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on 2023-503185-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503185-23-00.